This page lists the cancer care hospitals in our directory offering Colon Cancer Treatment in UAE, including Burjeel Hospital for Advanced Surgery Dubai, Kings College Hospital Dubai, Aster Hospital Dubai. Each listing links through to the hospital's full profile page.
Ask us about colon cancer treatment in UAE
Share a few details and our care coordination team will get back to you with next steps.
Compare 3 accredited hospitals for Cancer Care in UAE
Featured🇦🇪 Burjeel Hospital for Advanced Surgery Dubai
Ranks #1 in this list by listed rating (4.5/5 from 1 reviews).
🇦🇪 Kings College Hospital Dubai
Ranks #2 in this list by listed rating (4.5/5 from 1 reviews).
🇦🇪 Aster Hospital Dubai
Ranks #3 in this list by listed rating (4.5/5 from 1 reviews).
How we selected these hospitals
A hospital appears on this page when Cancer Care is among its listed specialties and it is located in UAE. Hospitals are not ranked by a proprietary "best" score — the order follows the listed rating (highest first), the same field shown on each hospital's profile.
How to Select the Best Hospital for Colon Cancer Treatment in UAE?
Choosing the right hospital for colon cancer treatment is one of the most important decisions in your treatment journey. A few factors are worth weighing before you decide:
International Accreditation
Look for a hospital with international accreditation such as JCI or NABH — see the accreditation badges shown for each hospital below.
Specialization
Check that the hospital's listed specialties actually include cancer care rather than only general care.
Capacity and Track Record
Bed count and year established (shown below for each hospital) are a reasonable proxy for scale and operating experience.
Transparent Costs
Ask for an itemised, all-inclusive estimate — hospital charges, room category and stay — before you travel. Our cost calculator (linked below) gives a starting estimate.
Understanding Colon Cancer Treatment
Colon cancer treatment encompasses a spectrum of interventions—from minimally invasive laparoscopic and robotic-assisted colectomy to precision-targeted systemic therapies—with curative resection success rates exceeding 90% for Stage I–II disease and meaningful 5-year survival rates of 70–75% for Stage III when treated at high-volume oncology centers. International patients increasingly choose India and the UAE for colon cancer care, benefiting from JCI- and NABH/DHA-accredited hospitals, multidisciplinary tumor boards, and access to advanced platforms such as the da Vinci robotic surgery system, all at costs 40–70% below Western benchmarks. GAF Healthcare coordinates every step of the medical journey—from pre-travel diagnostic review to post-discharge follow-up—ensuring seamless, clinically rigorous care for patients traveling from Europe, Africa, the Middle East, and beyond. Hospital Stay: 7–14 days (varies by surgical approach: open vs. laparoscopic/robotic, and adjuvant therapy initiation) • Total Stay in Country (Fit-to-Fly): 3–6 weeks (fit-to-fly clearance depends on surgical wound healing, stoma management if applicable, and initiation of any adjuvant chemotherapy cycles) • Success Rate: 90–95% curative resection rate for Stage I–II; 70–75% 5-year overall survival for Stage III with adjuvant FOLFOX/CAPOX chemotherapy
Clinical Overview
Colorectal adenocarcinoma arising in the colon (large intestine) accounts for approximately 1.9 million new diagnoses globally each year, ranking as the third most commonly diagnosed malignancy worldwide. The disease originates predominantly from adenomatous polyps in the colonic mucosa; progressive accumulation of somatic mutations—classically along the APC/Wnt, KRAS, and TP53 pathways—drives transformation from benign polyp to invasive carcinoma. Physiologically, colonic tumors may obstruct normal transit (causing altered bowel habits, tenesmus, or frank obstruction), invade adjacent mesenteric vasculature and lymph nodes, and metastasize hematogenously to the liver, lungs, and peritoneum. Molecular profiling—including KRAS/NRAS/BRAF mutational status, microsatellite instability (MSI) or mismatch repair (MMR) status, and HER2 amplification—now directly dictates systemic therapy selection. The current standard of care for localized colon cancer is surgical resection with adequate mesenteric clearance (complete mesocolic excision, or CME), targeting a minimum of 12 lymph nodes for accurate TNM staging. For Stage III (node-positive) and selected high-risk Stage II tumors, adjuvant chemotherapy with FOLFOX (oxaliplatin + leucovorin + 5-fluorouracil) or CAPOX (capecitabine + oxaliplatin) delivered over 3–6 months substantially reduces recurrence risk. Metastatic disease (Stage IV) is managed with multi-agent chemotherapy backbones (FOLFOX, FOLFIRI), combined with biologic agents targeting VEGF (bevacizumab), EGFR (cetuximab or panitumumab in RAS wild-type tumors), or HER2 (trastuzumab + pertuzumab in HER2-amplified tumors). Immunotherapy with PD-1/PD-L1 checkpoint inhibitors (pembrolizumab, nivolumab) has demonstrated durable responses in MSI-high/dMMR tumors and is now approved as first-line therapy in this biomarker-selected population. Leading hospitals in India (Mumbai, Chennai, Delhi, Bengaluru) and the UAE (Dubai, Abu Dhabi) operate dedicated colorectal oncology programs staffed by fellowship-trained colorectal surgeons, medical oncologists, radiation oncologists, and specialized GI pathologists. Weekly multidisciplinary tumor board (MDT) conferences—modeled on Western academic center protocols—ensure that every treatment plan is evidence-based, individualized, and aligned with NCCN, ESMO, or ASCO guidelines. High patient volumes at these centers translate into superior surgical outcomes, lower complication rates, and robust experience with complex scenarios such as synchronous liver metastases, emergent colonic obstruction, and peritoneal carcinomatosis managed with cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC).
Who is a Candidate?
• ELIGIBLE CANDIDATES: • Patients with histologically confirmed colonic adenocarcinoma at any stage (I–IV) seeking curative resection, adjuvant chemotherapy, palliative systemic therapy, or a combination • Patients diagnosed with high-risk Stage II colon cancer (T4 lesion, perforated tumor, <12 lymph nodes examined, poor differentiation, lymphovascular or perineural invasion, elevated preoperative CEA >5 ng/mL) • Patients with Stage III disease (any T, N1–N2) who are candidates for R0 resection followed by adjuvant FOLFOX or CAPOX chemotherapy • Patients with oligometastatic Stage IV disease (limited hepatic or pulmonary metastases) potentially suitable for curative-intent resection of primary and metastatic sites, including simultaneous or staged hepatectomy • Patients with MSI-high/dMMR tumors at any stage who may benefit from immune checkpoint inhibitor therapy (pembrolizumab first-line) • Patients seeking second opinions on treatment planning, KRAS/NRAS/BRAF/MSI molecular profiling, or enrollment in clinical trial protocols at accredited centers • Patients with locally advanced rectal-sigmoid junction tumors evaluated for neoadjuvant short-course radiotherapy (SCRT) or total neoadjuvant therapy (TNT) prior to surgery • REQUIRED PRE-TRAVEL DIAGNOSTIC WORK-UP: • Colonoscopy with biopsy and histopathological confirmation (H&E staining, tumor grade) • High-resolution contrast-enhanced CT scan of chest, abdomen, and pelvis (CT CAP) for TNM staging • MRI pelvis (if sigmoid or rectosigmoid involvement to assess mesorectal fascia clearance) • PET-CT scan (FDG-18) for detection of occult metastatic disease in high-risk or Stage III–IV presentations • Serum tumor markers: CEA (carcinoembryonic antigen) and CA 19-9 • Extended molecular/biomarker panel: KRAS exon 2/3/4, NRAS exon 2/3/4, BRAF V600E, MSI/MMR by IHC or PCR, HER2 IHC/FISH, NTRK fusion testing • Complete blood count (CBC), comprehensive metabolic panel (CMP), LFTs, coagulation profile (PT/INR) • Echocardiogram (ECHO) and ECG for patients aged >60 or with cardiac comorbidities prior to major surgery • Nutritional assessment (albumin, pre-albumin) and risk scoring: ASA physical status classification, Revised Cardiac Risk Index (RCRI), P-POSSUM score for surgical risk stratification • Pulmonary function tests (PFTs) if significant lung involvement or prior smoking history • RELATIVE CONTRAINDICATIONS (REQUIRE MDT EVALUATION): • Uncontrolled active infection or sepsis from colonic perforation requiring emergency local stabilization before transfer • Severe cardiac dysfunction (NYHA Class III–IV heart failure, recent MI within 3 months) without pre-operative optimization • Extensive peritoneal carcinomatosis with Peritoneal Cancer Index (PCI) >20, indicating limited benefit from CRS/HIPEC • Significant hepatic dysfunction (Child-Pugh B or C) precluding safe hepatectomy in synchronous metastatic disease • Poor performance status (ECOG PS 3–4) that precludes major abdominal surgery or full-dose systemic chemotherapy • Uncorrected severe coagulopathy • Patient inability or unwillingness to remain in-country for minimum required post-operative follow-up period
Treatment Options & Approaches
SURGICAL APPROACHES: 1. Open Colectomy (Traditional): Midline laparotomy with segmental resection (right hemicolectomy, left hemicolectomy, sigmoid colectomy, transverse colectomy, or subtotal colectomy depending on tumor location) with complete mesocolic excision (CME) and central vascular ligation (CVL). CME is the colonic equivalent of total mesorectal excision (TME) for rectal cancer and has been shown to reduce local recurrence. Historically the standard approach; now primarily reserved for emergent presentations (obstruction, perforation), bulky T4b tumors with adjacent organ invasion, or limited laparoscopic/robotic access. 2. Laparoscopic Colectomy: Minimally invasive 4–5 port technique offering equivalent oncological outcomes to open resection for Stage I–III colon cancer (validated by landmark COST, COLOR, and CLASICC trials). Advantages include significantly reduced postoperative pain, shorter hospital stay (4–7 days vs. 7–10 days for open), faster return of bowel function, reduced wound complications, and earlier eligibility for adjuvant chemotherapy initiation. 3. Robotic-Assisted Colectomy (da Vinci Si/Xi Platform): Increasingly adopted at high-volume centers in India and the UAE. The robotic platform provides 3D high-definition visualization, 7-degree-of-freedom wristed instrumentation, and superior dexterity in confined anatomical spaces (e.g., pelvis, splenic flexure). Particularly advantageous for obese patients, complex anatomy, and left-sided or sigmoid resections. Associated with lower conversion-to-open rates compared to standard laparoscopy. Available at Apollo Hospitals, Fortis, Medanta, Aster, Cleveland Clinic Abu Dhabi, American Hospital Dubai, and Mediclinic City Hospital. 4. Transanal Minimally Invasive Surgery (TAMIS) / Transanal Total Mesorectal Excision (TaTME): Applied for distal sigmoid and rectosigmoid tumors; allows bottom-up dissection with superior visualization of the distal mesorectal plane, reducing circumferential resection margin (CRM) positivity rates. 5. Cytoreductive Surgery (CRS) + HIPEC: For selected patients with peritoneal-only metastatic disease and Peritoneal Cancer Index (PCI) ≤15–20. Involves surgical debulking of all visible peritoneal deposits followed by intraperitoneal perfusion with heated chemotherapy (typically oxaliplatin or mitomycin C at 41–43°C for 30–90 minutes). Associated with median overall survival of 30–63 months at specialized centers—a significant improvement over systemic chemotherapy alone. 6. Laparoscopic or Open Hepatectomy for Synchronous Liver Metastases: For oligometastatic Stage IV disease, curative-intent liver resection performed simultaneously or in a staged fashion after colorectal resection offers 5-year survival rates of 25–40%. Preoperative portal vein embolization (PVE) or ALPPS procedure may be employed to augment future liver remnant (FLR) volume. SYSTEMIC THERAPY OPTIONS: 7. Adjuvant Chemotherapy (Stage III and High-Risk Stage II): FOLFOX (oxaliplatin 85 mg/m² + leucovorin + 5-FU bolus/infusion, every 2 weeks × 12 cycles) or CAPOX (capecitabine 1000 mg/m² BID D1–14 + oxaliplatin 130 mg/m² D1, every 3 weeks × 8 cycles). Duration: 3–6 months (IDEA collaboration data support 3-month CAPOX for low-risk Stage III with equivalent efficacy and reduced neurotoxicity). 8. First-Line Metastatic Chemotherapy: FOLFOX or FOLFIRI (irinotecan + leucovorin + 5-FU) as backbone, combined with bevacizumab (anti-VEGF) in all-comers or cetuximab/panitumumab (anti-EGFR) in RAS/RAF wild-type left-sided tumors. FOLFOXIRI + bevacizumab (TRIBE regimen) for fit patients with high tumor burden requiring rapid response. 9. Immunotherapy: Pembrolizumab (PD-1 inhibitor) as first-line monotherapy for MSI-high/dMMR metastatic colon cancer (KEYNOTE-177 trial: mPFS 16.5 months vs. 8.2 months for chemotherapy). Nivolumab ± ipilimumab as second-line option. 10. Targeted Therapy: BRAF V600E-mutated tumors: encorafenib + cetuximab (BEACON-CRC trial). HER2-amplified/overexpressed tumors: trastuzumab + pertuzumab or tucatinib + trastuzumab. NTRK-fusion positive tumors: larotrectinib or entrectinib (tumor-agnostic approval). 11. Radiation Therapy: Not a primary modality for colon cancer (unlike rectal cancer), but palliative radiotherapy is employed for painful bone metastases, brain metastases, or localized bleeding from unresectable primary tumors. Stereotactic body radiotherapy (SBRT/SABR) for oligometastatic hepatic or pulmonary lesions in patients not suitable for surgical resection. 12. Enhanced Recovery After Surgery (ERAS) Protocol: All major centers apply multimodal ERAS pathways including preoperative carbohydrate loading, minimization of opioid analgesia (TAP blocks, epidurals), early enteral feeding, and early ambulation—reducing hospital length of stay by 30–40% and lowering complication rates.
Recovery
PHASE 1 — PRE-TRAVEL PREPARATION (2–4 weeks before departure): • Patient submits existing medical records (pathology report, imaging, biomarker panel) to GAF Healthcare's clinical coordinator for review by the assigned colorectal oncology MDT. • GAF Healthcare facilitates e-Medical Visa application for India (typically processed in 3–5 business days) or coordinates entry visa/visa-on-arrival for UAE destinations. • Oncology case summary and provisional treatment recommendation prepared by the receiving hospital's tumor board and shared with patient prior to travel. • Preadmission optimization: nutritional supplementation (high-protein oral feeds if albumin <3.5 g/dL), iron infusion for preoperative anemia correction (target Hb >10 g/dL), anticoagulation bridging plan, and cessation of antiplatelet agents per surgeon guidance. • GAF Healthcare arranges airport reception, ground transfer, and accommodation for patient and one attendant near the treating hospital. PHASE 2 — HOSPITAL ADMISSION & PREOPERATIVE WORKUP (Days 1–3): • Day 1: Hospital admission, reassessment by colorectal surgeon and anesthesiologist. Repeat or additional imaging ordered if prior studies are >8 weeks old or inadequate quality. • Day 2: Anesthesia pre-assessment (RCRI, airway assessment, ECHO review). Stoma nurse consultation if defunctioning ileostomy or permanent colostomy is anticipated. Patient education on ERAS protocol, expected postoperative trajectory, and stoma management. • Day 3 (pre-operative): Mechanical bowel preparation (surgeon-dependent), low-residue diet, carbohydrate loading with clear maltodextrin drink until 2 hours pre-surgery, VTE prophylaxis (LMWH), and antibiotic prophylaxis plan confirmed. PHASE 3 — SURGERY (Day 3 or 4): • Procedure duration: 2–5 hours depending on extent of resection, approach (laparoscopic/robotic/open), and need for simultaneous hepatectomy or HIPEC. • Intraoperative: General anesthesia with thoracic epidural or TAP block for enhanced analgesia. Intraoperative colonoscopy may be used for tumor localization. Sentinel lymph node mapping with fluorescent dye (ICG near-infrared imaging) increasingly employed at robotic centers. • Specimen sent for urgent frozen section (margins) and definitive histopathology with full nodal harvest, lymphovascular invasion assessment, and confirmed molecular panel. • Patient transferred to surgical HDU/ICU for 12–24 hours of close hemodynamic monitoring. PHASE 4 — POST-OPERATIVE RECOVERY IN HOSPITAL (Days 4–14): • Day 1 post-op: Urinary catheter removed (laparoscopic/robotic cases), oral clear liquids commenced, early ambulation with physiotherapist support. • Days 2–3 post-op: Epidural or regional analgesia weaned; step-down to oral multimodal analgesia. Soft diet introduced. Drain output monitored for anastomotic leak or hemorrhage. • Days 4–5 post-op: Return of bowel function confirmed (flatus/stool). Regular diet tolerated. Wound inspection. Stoma output assessed and patient/attendant trained in stoma care if applicable. • Days 5–7 post-op (laparoscopic/robotic): Discharge criteria met if patient is afebrile, tolerating full diet, ambulating independently, and stoma/wound is stable. Oral analgesics only. • Days 7–14 post-op (open or complex resection/HIPEC): Extended monitoring, nutritional support, and physiotherapy. Final histopathology report typically available by Day 7–10. PHASE 5 — POST-DISCHARGE RECOVERY & ADJUVANT PLANNING (Weeks 2–6 in country): • Week 2 post-op: Outpatient wound review, staple/suture removal. Oncologist consultation to discuss final pathology, definitive TNM stage, and adjuvant therapy plan. • Weeks 3–4: If adjuvant chemotherapy is indicated, PICC line or port-a-cath insertion and Cycle 1 of FOLFOX/CAPOX may be initiated in-country if patient's travel timeline allows. Alternatively, a detailed written treatment protocol is provided for continuation at the patient's home country oncologist. • Week 4–6 (Fit-to-Fly Assessment): Surgeon confirms: surgical wound fully healed, no anastomotic leak evidence, stoma functioning well (if present), no active VTE, and patient comfortable for long-haul travel. VTE prophylaxis (LMWH injections) prescribed for the flight. Comprehensive discharge summary, operative report, histopathology, and imaging CDs provided. • Post-departure: GAF Healthcare arranges telemedicine follow-up appointments with the treating surgeon and oncologist at 6 weeks, 3 months, and 6 months post-surgery.
Risks to be aware of
Colon cancer surgery and systemic treatment carry well-characterized risks that patients must discuss candidly with their treating team. Surgical risks include anastomotic leak (occurring in 2–7% of cases, higher in low pelvic anastomoses and immunocompromised patients), which may require reoperation or temporary stoma creation; wound infection (5–15%); intra-abdominal abscess; prolonged ileus or small bowel obstruction; hemorrhage requiring transfusion; and urinary or sexual dysfunction from autonomic nerve injury during pelvic dissection. Laparoscopic and robotic approaches reduce wound-related complications but carry specific risks of port-site hernia and rare vascular injury during trocar insertion. Stoma complications—including retraction, prolapse, parastomal hernia, and skin breakdown—affect up to 30% of patients with permanent or long-term stomas and require specialist stoma nurse follow-up. HIPEC carries additional risks of systemic toxicity from intraperitoneal chemotherapy absorption, renal impairment, and prolonged recovery (ICU stays of 3–5 days). Chemotherapy-related toxicities include oxaliplatin-induced peripheral neuropathy (cumulative dose-dependent, affecting up to 90% of patients to some degree; severe in 10–15%), 5-FU-related mucositis and myelosuppression, capecitabine hand-foot syndrome (palmar-plantar erythrodysesthesia), and irinotecan-associated cholinergic syndrome and delayed diarrhea. Bevacizumab carries risks of hypertension, proteinuria, impaired wound healing (necessitating cessation 4–6 weeks before any surgery), thromboembolic events, and rare gastrointestinal perforation. EGFR inhibitors (cetuximab, panitumumab) cause acneiform rash (a biomarker of efficacy), hypomagnesemia, and infusion reactions. Immunotherapy with checkpoint inhibitors risks immune-related adverse events (irAEs) including colitis, pneumonitis, hepatitis, endocrinopathies (thyroiditis, adrenal insufficiency), and rare cardiac myocarditis. Long-haul air travel post-surgery confers elevated DVT/PE risk; LMWH prophylaxis and compression stockings are mandatory for flights exceeding 4 hours. All international patients should carry comprehensive travel health insurance covering in-country complications and medical repatriation.
Why GAF Healthcare
GAF Healthcare provides a fully integrated medical tourism coordination service, removing logistical complexity so patients can focus entirely on their recovery. VISA ASSISTANCE — INDIA: GAF Healthcare's documentation team guides patients through the Indian e-Medical Visa application (eMV) available to citizens of over 170 countries. The eMV is applied for online, is typically approved within 3–5 business days, and permits a stay of up to 60 days extendable to 6 months for ongoing treatment. GAF provides a hospital-issued invitation letter (required for eMV application), confirmed appointment letters, and cost estimates in the required format for the Indian embassy. One attendant companion visa (e-Medical Attendant Visa) is facilitated simultaneously. VISA ASSISTANCE — UAE (DUBAI/ABU DHABI): Citizens of GCC countries, most EU nations, UK, USA, Canada, Australia, and many other countries receive visa-free entry or visa-on-arrival for stays of 30–90 days. For nationals requiring advance visas, GAF Healthcare coordinates with the receiving hospital in Dubai or Abu Dhabi to issue a medical treatment visa invitation letter, simplifying the application. Patients receiving treatment under Dubai Health Authority (DHA) or Abu Dhabi Department of Health (DoH) licensed facilities may access expedited medical visit pathways. AIRPORT & GROUND LOGISTICS: GAF Healthcare arranges private, wheelchair-accessible airport pickup (for patients with mobility limitations post-operatively) and drop-off in both India and the UAE. All transfers are in air-conditioned vehicles with a trained patient liaison escort. DEDICATED PATIENT COORDINATOR: Each patient is assigned a named GAF Healthcare case manager who speaks the patient's language (Arabic, Russian, French, Swahili, and other languages available) and liaises directly with the hospital's international patient services department. The coordinator is reachable 24/7 during the in-country stay for any medical or logistical queries. ACCOMMODATION: GAF Healthcare pre-negotiates preferred rates at hospital-affiliated guest houses, service apartments, and partner hotels within 5–15 minutes of the treating hospital—suitable for the patient's attendant during the inpatient stay, and for both patient and attendant during the post-discharge recovery phase. Accommodation options range from budget-comfortable to five-star, based on patient preference. TELEMEDICINE & FOLLOW-UP: Following discharge and return home, GAF Healthcare schedules structured telemedicine consultations with the treating surgeon and oncologist. Digital copies of all medical records—operative reports, histopathology, imaging (CD/DICOM), and discharge summaries—are provided in a structured digital health file for sharing with the patient's home-country physicians. CURRENCY & PAYMENTS: Treatment costs may be settled via international wire transfer, credit card, or through insurance direct-billing arrangements (available at select JCI-accredited hospitals in India and UAE). GAF Healthcare provides itemized cost estimates upfront with no hidden charges.
Common questions about Colon Cancer Treatment
What is the cost of Colon Cancer Treatment in India vs. the UAE?
How long do I need to stay in the country before I am fit to fly home after Colon Cancer Treatment?
What is the success rate of Colon Cancer Treatment?
Related pages
How GAF Healthcare Assists in Choosing the Best Hospital for Colon Cancer Treatment in UAE
Discover the Top Hospitals for Colon Cancer Treatment in UAE
This page lists 3 accredited cancer care hospitals in UAE, so you can compare accreditation, specialties and bed capacity in one place.
Support When You Need It Most
Share your medical reports with us on WhatsApp or email. Our medical team reviews them and comes back with a recommended hospital and treatment plan for your case.
Transparent, All-Inclusive Costs
We provide a single, itemised quote covering hospital charges and stay — no hidden fees, and there's no charge for requesting an estimate. Use our cost calculator alongside this page for a first estimate.
Visa, Travel and Stay Coordination
Once you choose a hospital, we help arrange the medical visa invitation letter, hotel or serviced-apartment booking nearby, airport pickup and transport to your appointments.
Curious what treatment might cost for your case? Use our cost calculator for a personalized estimate.
Frequently asked questions about colon cancer treatment in UAE
How many cancer care hospitals are listed in UAE?
How do you choose which hospitals to list?
How much does treatment cost in UAE?
Which cities in UAE have cancer care hospitals listed?
Next Step
Share your medical reports with us and our team will recommend a hospital and treatment plan for colon cancer treatment in UAE.
Contact us to report an inaccuracy on this page.